Last reviewed · How we verify
Omaveloxolone Lotion 3%
At a glance
| Generic name | Omaveloxolone Lotion 3% |
|---|---|
| Also known as | RTA 408 Lotion 3% |
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE (PHASE2)
- RTA 408 Lotion in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omaveloxolone Lotion 3% CI brief — competitive landscape report
- Omaveloxolone Lotion 3% updates RSS · CI watch RSS
- Biogen portfolio CI